Physician profile
Robert George Johnson
NPI 1104846351
$760.22
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $678 · 2022: $82.13.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $250.97 | 2019-2022 | |
| Amgen INC. | $93.11 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.79 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.29 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.34 | 2019 | |
| Lilly USA, LLC | $36.12 | 2019 | |
| Merck Sharp & Dohme LLC | $27.41 | 2019 | |
| Boston Scientific Corporation | $26.93 | 2019 | |
| Glaxosmithkline, LLC. | $23.02 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $22.95 | 2019 | |
| Astellas Pharma US INC | $20.67 | 2019 | |
| Amarin Pharma, INC. | $19.15 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.13 | 2019 | |
| Abbott Laboratories | $14.28 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.97 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $12.66 | 2019 | |
| Daiichi Sankyo INC. | $12.43 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.